Rhabdomyosarcoma Clinical Trials

Find Rhabdomyosarcoma Clinical Trials Near You

A Single-Center Clinical Study Evaluating the Safety and Antitumor Activity of Entinostat in Children With Malignant Soft Tissue Sarcoma Harboring PAX-family Gene Abnormalities

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1
SUMMARY

Pediatric soft tissue sarcomas (STS) are a group of malignant tumors originating from primitive mesenchymal tissues and account for approximately 7% of childhood cancers. STS are broadly classified into rhabdomyosarcoma (RMS) and non-rhabdomyosarcoma soft tissue sarcoma (NRSTS). RMS accounts for approximately one half of pediatric STS. As reported, PAX fusion-positive RMS is more aggressive than fusion-negative RMS, with higher metastatic potential and poorer prognosis. Based on the unmet therapeutic need in pediatric sarcoma with PAX-family abnormalities, this study is intended to evaluate the preliminary safety and antitumor activity of entinostat with or without chemontherapy.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 1
Maximum Age: 18
Healthy Volunteers: f
View:

• Age \>1 year and ≤18 years.

• Histologically confirmed malignant soft tissue sarcoma that is PAX3-FOXO1- or PAX7-FOXO1-fusion positive or has another PAX-family gene abnormality.

• Clinical disease status: (a) monotherapy cohort: completion of standard backbone chemotherapy and/or radiotherapy with a favorable clinical response (CR or PR); (b) combination cohort: inadequate response following standard chemotherapy and/or radiotherapy, or recurrent/progressive disease.

• Karnofsky Performance Status (KPS) ≥50 or Lansky Performance Status (LPS) ≥50.

• Adequate bone marrow function: ANC ≥0.5 × 10\^9/L, platelet count ≥50 × 10\^9/L, hemoglobin ≥70 g/L, and WBC ≥1.5 × 10\^9/L, with values not exceeding the upper limit of normal.

• Life expectancy of at least 6 months.

• Written informed consent obtained.

Locations
Other Locations
China
Beijing Tongren Hospital
RECRUITING
Beijing
Time Frame
Start Date: 2025-03-15
Estimated Completion Date: 2027-03-31
Participants
Target number of participants: 16
Treatments
Experimental: Cohort 1- entinistat monotherapy
After completion of prior chemotherapy and/or radiotherapy, patients who have achieved CR/PR will receive entinostat as consolidation therapy.
Experimental: Cohort 2 - entinostat combined with chemotherapy
Patients with recurrent or progressive disease will receive entinostat in combination with alternating VAC/VTC chemotherapy.
Sponsors
Leads: Beijing Tongren Hospital

This content was sourced from clinicaltrials.gov